Document:

Stock Issuance Agreement

 Exhibit 10.2 
 STOCK ISSUANCE AGREEMENT 
 THIS STOCK
ISSUANCE AGREEMENT (“Agreement”) is made and entered into as of June 5, 2012 (the “Effective Date”), by and among Oragenics, Inc., a Florida corporation (the
“Company”) and Intrexon Corporation, a Virginia corporation (“Intrexon”). 
 A.
Concurrently with the execution of this Agreement, the Company is entering into an Exclusive Channel Collaboration Agreement with Intrexon (the “Channel Agreement”), pursuant to which Intrexon is licensing the rights to certain
technology to the Company; and 
 B. In consideration of Intrexon’s license to the Company under the Channel
Agreement, the Company has agreed to issue to Intrexon certain shares of the Company’s common stock, par value $0.001 per share (“Common Stock”) in accordance with the terms and conditions of this Agreement. 

NOW THEREFORE, in consideration of the mutual covenants contained in this Agreement and for other good and valuable consideration,
the receipt of which is hereby acknowledged, the Company and Intrexon hereby agree as follows: 
 SECTION 1.
AUTHORIZATION OF ISSUANCE OF SHARES. 
 1.1 Technology Access Fee Shares. Subject to the terms and conditions of this Agreement, the Company has authorized the issuance to Intrexon of 4,392,425 shares of the Company’s Common
Stock, “Technology Access Fee Shares”) at the Technology Access Fee Shares Closing (as hereinafter defined). 

1.2 Milestones. Subject to the terms and conditions of this Agreement and the Channel Agreement, upon the attainment of the
commercialization milestones as set forth below, and with respect to only the first Oragenics Product developed under the Channel Agreement that reaches any such milestone, the Company has agreed to make certain milestone payments (each a
“Milestone Payment” and together “Milestone Payments”) to Intrexon in the form of shares of Company Common Stock, or at the Company’s sole option make a cash payment to Intrexon (based upon the fair market
value of the shares) on the date the Milestone Event (as defined below) is achieved: 
 (a) upon the filing of the first
Investigational New Drug application (“IND”) with the U.S. Food and Drug Administration for an Oragenics Product (as that term is defined in the Channel Agreement), or alternatively the filing of the first equivalent regulatory
filing with a foreign regulatory agency, that number of shares of Common Stock (the “IND Milestone Shares”) equal to the number of shares of Common Stock comprising 1% of the Base Shares (as hereafter defined). For purposes herein,
the Base Shares means (i) the number of shares of Common Stock together with any securities or instruments convertible or exercisable for shares of Common Stock issued and outstanding at the time of the relevant Milestone Event, (ii) minus
any shares issuable upon conversion of Capital Inducement Securities. For purposes herein, Capital Inducement Securities means warrants or other convertible securities of the Company issued to investors in connection with a debt or equity investment
in the Company that are issued in addition to the primary investment securities and in an amount not to exceed 10% of the overall number of shares issued in the investment (on an as-converted to Common Stock basis); 

(b) upon the dosing of the first patient in the first Phase 2 clinical study with an Oragenics Product, that number of shares
(the “Phase 2 Milestone Shares”) equal to the number of shares of Common Stock comprising 1.5% of the Base Shares; 
 (c) upon the dosing of the first patient in the first Phase 3 clinical study with an Oragenics Product, that number of shares (the “Phase 3 Milestone Shares”) equal to the number
of shares of Common Stock comprising 2% of the Base Shares; 

 (d) upon the filing of the first New Drug Application (“NDA”) or Biologics
License Application (“BLA”) with the U.S. Food and Drug Administration for an Oragenics Product, or alternatively the filing of the first equivalent regulatory filing with a foreign regulatory agency, that number of shares (the
“NDA Milestone Shares”) equal to the number of shares of Common Stock comprising 2.5% of the Base Shares; and 

(e) upon the granting of the first regulatory approval of an Oragenics Product, that number of shares (the “Approval
Milestone Shares”) equal to the number of shares of Common Stock comprising 3% of the Base Shares. 
 The number of
shares of Common Stock to be issued under each of subsections (a) through (e) of this Section 1.2 shall be rounded down to the nearest whole share. The event giving rise to an issuance of shares under subsections (a) through
(e) of this Section 1.2 shall be a “Milestone Event” and together, the “Milestone Events.” A Milestone Payment shall be due within thirty days following the date of the occurrence of a Milestone Event.

 1.3 Company Sale. In the event that the Company consummates a Company Sale (as defined below in
Section 11.13) prior to any one or more of the Subsequent Closings, and the Channel Agreement is transferred or assigned to the buyer or assigned to the buyer in connection with such Company Sale, the Company and Intrexon agree that Intrexon
shall be entitled to receive and any successor in interest to Company be obligated to pay, in lieu of the specific Milestone Payment amounts set forth in Section 1.2, at each Subsequent Closing following the Company Sale a minimum milestone
payment in cash in an amount set forth in the following subsections (a) through (e) of this Section 1.3 (the “Minimum Milestone Amounts”). 
 (a) If the closing for the Milestone Event in Section 1.2(a) occurs after a Company Sale, Intrexon will receive at that closing, and in lieu of the IND Milestone Shares, the greater of
(i) $1,500,000 or (ii) the fair market value that the IND Milestone Shares would have been entitled to receive had they been outstanding at the consummation of the Company Sale. 

(b) If the closing for the Milestone Event in Section 1.2(b) occurs after Company, Intrexon will receive at that closing,
and in lieu of the Phase 2 Milestone Shares, the greater of (i) $5,000,000 or (ii) the fair market value that the Phase 2 Milestone Shares would have been entitled to receive had they been outstanding at the consummation of the Company
Sale. 
 (c) If the closing for the Milestone Event in Section 1.2(c) occurs after a Company Sale, Intrexon will
receive at that closing, and in lieu of the Phase 3 Milestone Shares, the greater of (i) $10,000,000 or (ii) the fair market value that the Phase 3 Milestone Shares would have been entitled to receive had they been outstanding at the
consummation of the Company Sale. 
 (d) If the closing for the Milestone Event in Section 1.2(d) occurs after a
Company Sale, Intrexon will receive at that closing, and in lieu of the NDA Milestone Shares, the greater of (i) $15,000,000 or (ii) the fair market value that the NDA Milestone Shares would have been entitled to receive had they been
outstanding at the consummation of the Company Sale. 
 (e) If the closing for the Milestone Event in
Section 1.2(e) occurs after a Company Sale, Intrexon will receive at that closing, and in lieu of the Approval Milestone Shares, the greater of (i) $25,000,000 or (ii) the fair market value that the Approval Milestone Shares would
have been entitled to receive had they been outstanding at the consummation of the Company Sale. 
 The payment of a Minimum Milestone Amount
due under subsections (a) through (e) above will be due within thirty days (30) following the date of the occurrence of the respective Milestone Event. 
 1.4 Capital Adjustments. If after the date hereof (i) the outstanding shares of the Company’s Common Stock shall be subdivided or split into a greater number of shares or a
dividend in Common Stock shall be paid in respect of such Common Stock or (ii) the outstanding shares of Common Stock are combined, then all share quantities in this Agreement not yet issued shall be appropriately adjusted to reflect such stock
split, stock dividend or conjunction. If 

 
after the date hereof (i) the Company shall pay a dividend in securities of the Company (other than in Common Stock) or of other property (including cash) on the Common Stock, or
(ii) there shall occur any merger, consolidation, capital reorganization or reclassification in which the Common Stock is converted or exchanged for securities, cash or other property, the class or series of stock constituting the Common Stock
for purposes of this Agreement, shall be appropriately adjusted to reflect such other dividend, merger, consolidation, capital reorganization or reclassification. After any event referenced in clauses (i) through (ii) of the immediately
preceding sentence is consummated, if applicable, all references herein to the Company’s Common Stock shall be deemed to refer to the capital stock or property (including cash) into or for which the Common Stock was converted or exchanged, with
the necessary changes in detail. 
 SECTION 2. CLOSING AND DELIVERY

 2.1 Issuance of Technology Access Fee Shares. Subject to the terms and conditions of this
Agreement, the Channel Agreement and in reliance upon the representations, warranties and agreements contained herein, the Company will issue to Intrexon the Technology Access Fee Shares. The Parties agree that the consideration received by the
Company hereunder shall be the execution and delivery by Intrexon of the Channel Agreement which consideration is at least equal to the par value of the Technology Access Fee Shares issued hereunder. 

2.2 Closings. Each closing of an issuance of shares pursuant to this Agreement shall be held at the offices of Shumaker,
Loop & Kendrick, LLP, 101 East Kennedy Blvd., Suite 2800, Tampa, Florida 33602 or at such other place as the Company and Intrexon may agree, as follows: 
 (a) the closing of the issuance of the Technology Access Fee Shares will occur, subject to the conditions set forth in Section 9 hereof and applicable to the Technology Access Fee Shares
Closing, (i) on the fourth business day following any necessary approvals of this Agreement by stockholders and/or directors of Company (the “Stockholder Approval”), or (ii) on such other date as Intrexon and the Company
may agree upon (in either case, the “Technology Access Fee Shares Closing”); and 
 (b) the issuance of
the IND Milestone Shares, the Phase 2 Milestone Shares, the Phase 3 Milestone Shares, the NDA Milestone Shares, and the Approval Milestone Shares will each occur, subject to achievement of their respective Milestone Events and the conditions set
forth in Section 9 hereof and applicable to the Subsequent Closings, on the earlier of (i) the thirtieth day following their respective triggering Milestone Event as set forth in sections 1.2(b) through 1.2(f) above, and (ii) such
other date as Intrexon and the Company may agree (singularly, a “Subsequent Closing,” or collectively, the “Subsequent Closings”). 
 The Technology Access Fee Closing and the Subsequent Closings are collectively hereinafter referred to as the “Closings” and individually as a “Closing”. 

2.3 Delivery of the Shares. Promptly following a Closing, the Company shall deliver to Intrexon a certificate representing
the shares required to be issued at such Closing, registered in the name of Intrexon. 
 SECTION 3.
REPRESENTATIONS AND WARRANTIES OF THE COMPANY. 
 Subject to and except as set forth in the SEC Documents or on the Schedule of Exceptions which is arranged in sections corresponding to the sub-section numbered provisions contained below in this Section,
the Company hereby represents and warrants to Intrexon as of the date hereof as follows: 
 3.1 Organization, Good
Standing and Power. The Company is a corporation duly incorporated, validly existing and in good standing under the laws of the State of Florida and has the requisite corporate power to own, lease and operate its properties and assets and to
conduct its business as it is now being conducted and as described in the reports filed by the Company with the Securities and Exchange Commission (the “Commission”) pursuant to the reporting requirements of the Securities Exchange
Act of 1934, as amended (the “Exchange Act”), since the end of its most recently completed fiscal year through the date hereof, including, without limitation, its most recent report on Form 10-Q. The Company does not have any
subsidiaries other than those identified in its most recent report on Form 10-Q. 

 
The Company is qualified to do business as a foreign corporation and is in good standing in every jurisdiction in which the nature of the business conducted or property owned by it makes such
qualification necessary, except for any jurisdiction(s) (alone or in the aggregate) in which the failure to be so qualified will not have a Material Adverse Effect. For the purposes of this Agreement, “Material Adverse Effect” means
any effect on the business, operations, properties or financial condition of the Company that is material and adverse to the Company, taken as a whole, and any condition, circumstance or situation that would prohibit the Company from entering into
and performing any of its obligations hereunder. 
 3.2 Authorization; Enforcement. The Company has the requisite
corporate power and authority to enter into and perform this Agreement and to issue the shares in accordance with the terms hereof. The execution, delivery and performance of this Agreement by the Company and the consummation by it of the
transactions contemplated hereby have been duly and validly authorized by all necessary corporate action, and no further consent or authorization of the Company, its board of directors or stockholders is required, except pursuant to Section 8.
When executed and delivered by the Company, this Agreement shall constitute a valid and binding obligation of the Company enforceable against the Company in accordance with its terms, except as such enforceability may be limited by applicable
bankruptcy, reorganization, moratorium, liquidation, conservatorship, receivership or similar laws relating to, or affecting generally the enforcement of, creditor’s rights and remedies or by other equitable principles of general application.
The Company’s board of directors, at a meeting duly called and held, adopted resolutions approving the transactions contemplated hereby, including the issuance of the Technology Access Fee Shares. 

3.3 Issuance of Shares. The shares to be issued and sold hereunder have been duly authorized by all necessary corporate
action and, when issued in accordance with the terms hereof, will be validly issued, fully paid and nonassessable. In addition, such shares will be free and clear of all liens, claims, charges, security interests or agreements, pledges, assignments,
covenants, restrictions or other encumbrances created by, or imposed by, the Company (collectively, “Encumbrances”) and rights of refusal of any kind imposed by the Company (other than restrictions on transfer under applicable
securities laws) and the holder of such shares shall be entitled to all rights accorded to a holder of Common Stock. As of the date hereof, 12,174,795 shares of the Company’s Common Stock are issued and outstanding. 

3.4 No Conflicts; Governmental Approvals. The execution, delivery and performance of the Agreement by the Company and the
consummation by the Company of the transactions contemplated hereby do not and will not (i) violate any provision of the Company’s Articles of Incorporation or Bylaws, each as amended to date, (ii) conflict with, or constitute a
default (or an event which with notice or lapse of time or both would become a default) under, or give to others any rights of termination, amendment, acceleration or cancellation of, any agreement, mortgage, deed of trust, indenture, note, bond,
license, lease agreement, instrument or obligation to which the Company is a party or by which the Company’s properties or assets are bound, or (iii) result in a violation of any federal, state, local or foreign statute, rule, regulation,
order, judgment or decree (including federal and state securities laws and regulations) applicable to the Company or by which any property or asset of the Company is bound or affected, except for such conflicts, defaults, terminations, amendments,
acceleration, cancellations and violations as would not, individually or in the aggregate, have a Material Adverse Effect. The Company is not required under federal, state, foreign or local law, rule or regulation to obtain any consent,
authorization or order of, or make any filing or registration with, any court or governmental agency in order for it to execute, deliver or perform any of its obligations under this Agreement or issue and sell the shares in accordance with the terms
hereof (other than any filings, consents and approvals which may be required to be made by the Company under applicable state and federal securities laws, rules or regulations prior to or subsequent to the Closing). 

3.5 Commission Documents, Financial Statements. The Common Stock of the Company is registered pursuant to
Section 12(g) of the Exchange Act. During the year preceding this Agreement, the Company has timely filed all reports, schedules, forms, statements and other documents required to be filed by it with the Commission pursuant to the reporting
requirements of the Exchange Act (the “SEC Documents”). At the times of their respective filing, all such reports, schedules, forms, statements and other documents complied in all material respects with the requirements of the
Exchange Act and the rules and regulations of the Commission promulgated thereunder. At the times of their respective filings, such reports, schedules, forms, statements and other documents did not contain any untrue statement of a material fact or
omit to state a material fact required to be stated therein or necessary in order to make the statements therein, in 

 
light of the circumstances under which they were made, not misleading. As of their respective dates, the financial statements of the Company included in the Commission Documents complied in all
material respects with applicable accounting requirements and the published rules and regulations of the Commission or other applicable rules and regulations with respect thereto. Such financial statements have been prepared in accordance with
generally accepted accounting principles applied on a consistent basis during the periods involved (except (i) as may be otherwise indicated in such financial statements or the notes thereto or (ii) in the case of unaudited interim
statements, to the extent they may not include footnotes or may be condensed or summary statements), and fairly present in all material respects the consolidated financial position of the Company as of the dates thereof and the results of operations
and cash flows for the periods then ended (subject, in the case of unaudited statements, to normal year-end audit adjustments). 

3.6 Accountants. Mayer Hoffman McCann P.C. whose report on the financial statements of the Company is filed with the SEC in
the Company’s Annual Report on Form 10-K for the year ended December 31, 2011, were, at the time such report was issued, independent registered public accountants as required by the Securities Act of 1933 and the rules and regulations
promulgated thereunder (together, the “Securities Act”). 
 3.7 Internal Controls. The Company
has established and maintains a system of internal accounting controls sufficient to provide reasonable assurances that: (i) transactions are executed in accordance with management’s general or specific authorization;
(ii) transactions are recorded as necessary to permit preparation of financial statements in conformity with generally accepted accounting principles in the United States and to maintain accountability for assets; (iii) access to assets is
permitted only in accordance with management’s general or specific authorization; and (iv) the recorded accountability for assets is compared with existing assets at reasonable intervals and appropriate action is taken with respect to any
differences. 
 3.8 Disclosure Controls. The Company has established and maintains disclosure controls and
procedures (as such term is defined in Rules 13a-15 and 15d-15 under the Exchange Act). Since the date of the most recent evaluation of such disclosure controls and procedures, there have been no significant changes in internal controls or in other
factors that could significantly affect internal controls, including any corrective actions with regard to significant deficiencies and material weaknesses. The Company is in compliance in all material respects with all provisions currently in
effect and applicable to the Company of the Sarbanes-Oxley Act of 2002, and all rules and regulations promulgated thereunder or implementing the provisions thereof. 
 3.9 No Material Adverse Change. Except as disclosed in the Commission Documents, since March 31, 2012, the Company has not (i) experienced or suffered any Material Adverse Effect,
(ii) incurred any material liabilities, obligations, claims or losses (whether liquidated or unliquidated, secured or unsecured, absolute, accrued, contingent or otherwise) other than those incurred in the ordinary course of the Company’s
business or (iii) declared, made or paid any dividend or distribution of any kind on its capital stock. 
 3.10
No Undisclosed Events or Circumstances. Except as disclosed in the Commission Documents, since March 31, 2012, except for the consummation of the transactions contemplated herein, to the Company’s knowledge, no event or circumstance
has occurred or exists with respect to the Company or its businesses, properties, prospects, operations or financial condition, which, under applicable law, rule or regulation, requires public disclosure or announcement by the Company but which has
not been so publicly announced or disclosed. 
 3.11 Litigation. No action, suit, proceeding or investigation is
currently pending or, to the knowledge of the Company, has been threatened in writing against the Company that: (i) concerns or questions the validity of this Agreement; (ii) concerns or questions the right of the Company to enter into
this Agreement; or (iii) is reasonably likely to have a Material Adverse Effect. The Company is neither a party to nor subject to the provisions of any material order, writ, injunction, judgment or decree of any court or government agency or
instrumentality. There is no action, suit, proceeding or investigation by the Company currently pending or that the Company intends to initiate that would have a Material Adverse Effect. 

3.12 Compliance. Except for defaults or violations which are not reasonably likely to have a Material Adverse Effect, the
Company is not (i) in default under or in violation of (and no event has occurred that has not been waived that, with notice or lapse of time or both, would result in a default by the Company under), nor has the Company

 
received notice of a claim that it is in default under or that it is in violation of, any indenture, loan or credit agreement or any other agreement or instrument to which it is a party or by
which it or any of its properties is bound (whether or not such default or violation has been waived), (ii) is in violation of any order of any court, arbitrator or governmental body, or (iii) is or has been in violation of any statute,
rule or regulation of any governmental authority, including without limitation all foreign, federal, state and local laws, applicable to its business. 
 3.13 Intellectual Property 
 (a) To the best of its
knowledge, the Company has entered into agreements with each of its current and former officers, employees and consultants involved in research and development work, including development of the Company’s products and technology providing the
Company, to the extent permitted by law, with title and ownership to patents, patent applications, trade secrets and inventions conceived, developed, reduced to practice by such person, solely or jointly with other of such persons, during the period
of employment by the Company except where the failure to have entered into such an agreement would not have a Material Adverse Effect. The Company is not aware that any of its employees or consultants is in material violation thereof. 

(b) To the Company’s knowledge, the Company owns or possesses adequate rights to use all trademarks, service marks, trade
names, domain names, copyrights, patents, patent applications, inventions, know how (including trade secrets and other unpatented and/or unpatentable proprietary or confidential information, systems or procedures), and other intellectual property
rights (“Intellectual Property”) as are necessary for the conduct of its business as described in the Commission Documents. Except as described in the Commission Documents, (i) to the knowledge of the Company, there is no
infringement, misappropriation or violation by third parties of any such Intellectual Property; (ii) there is no pending or, to the knowledge of the Company, threatened action, suit, proceeding or claim by others against the Company challenging
the Company’s rights in or to any such Intellectual Property; (iii) the Intellectual Property owned by the Company and, to the knowledge of the Company, the Intellectual Property licensed to the Company has not been adjudged invalid or
unenforceable by a court of competent jurisdiction or applicable government agency, in whole or in part, and there is no pending or, to the knowledge of the Company, threatened action, suit, proceeding or claim by others challenging the validity or
scope of any such Intellectual Property; (iv) there is no pending or, to the knowledge of the Company, threatened action, suit, proceeding or claim by others against the Company that the Company infringes, misappropriates or otherwise violates
any Intellectual Property or other proprietary rights of others, and the Company has not received any written notice of such claim; and (v) to the Company’s knowledge, no employee of the Company is the subject of any claim or proceeding
involving a violation of any term of any employment contract, patent disclosure agreement, invention assignment agreement, non-competition agreement, non-solicitation agreement, nondisclosure agreement or any restrictive covenant to or with a former
employer where the basis of such violation relates to such employee’s employment with the Company or actions undertaken by the employee while employed with the Company, in each of (i) through (v), for any instances which would not,
individually or in the aggregate, result in a Material Adverse Effect. 
 3.14 FDA Compliance. 

(a) Except as described in the Commission Documents, the Company: (i) is in material compliance with all statutes, rules or
regulations applicable to the ownership, testing, development, manufacture, packaging, processing, use, distribution, marketing, labeling, promotion, sale, offer for sale, storage, import, export or disposal of any product that is under development,
manufactured or distributed by the Company (“Applicable Laws”); (ii) has not received any FDA Form 483, notice of adverse finding, warning letter, untitled letter or other correspondence or notice from the U.S. Food and Drug
Administration (the “FDA”) or any other federal, state, local or foreign governmental or regulatory authority alleging or asserting material noncompliance with any Applicable Laws or any licenses, certificates, approvals,
clearances, authorizations, permits and supplements or amendments thereto required by any such Applicable Laws (“Authorizations”), which would not, individually or in the aggregate, result in a Material Adverse Effect;
(iii) possesses all material Authorizations necessary for the operation of its business as described in the Commission Documents and such Authorizations are valid and in full force and effect and the Company is not in material violation of any
term of any such Authorizations; and (iv) since January 1, 2009: (A) has not received notice of any claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action from the FDA or any other federal,
state, local or foreign governmental or regulatory authority or third party alleging that any product operation or 

 
activity is in material violation of any Applicable Laws or Authorizations and has no knowledge that the FDA or any other federal, state, local or foreign governmental or regulatory authority or
third party is considering any such claim, litigation, arbitration, action, suit, investigation or proceeding; (B) has not received notice that the FDA or any other federal, state, local or foreign governmental or regulatory authority has
taken, is taking or intends to take action to limit, suspend, modify or revoke any material Authorizations and has no knowledge that the FDA or any other federal, state, local or foreign governmental or regulatory authority is considering such
action; (C) has filed, obtained, maintained or submitted all material reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments as required by any Applicable Laws or Authorizations and that all
such reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments were materially complete and correct on the date filed (or were corrected or supplemented by a subsequent submission); and (D) has
not, either voluntarily or involuntarily, initiated, conducted, or issued or caused to be initiated, conducted or issued, any recall, market withdrawal or replacement, safety alert, post sale warning, “dear doctor” letter, or other notice
or action relating to the alleged lack of safety or efficacy of any product or any alleged product defect or violation and, to the Company’s knowledge, no third party has initiated, conducted or intends to initiate any such notice or action.

 (b) Since January 1, 2009, and except to the extent disclosed in the Commission Documents, the Company has not
received any notices or correspondence from the FDA or any other federal, state, local or foreign governmental or regulatory authority requiring the termination, suspension or material modification of any studies, tests or preclinical or clinical
trials conducted by or on behalf of the Company. 
 3.15 General Healthcare Regulatory Compliance. 

(a) As used in this subsection: 
 (i) “Governmental Entity” means any national, federal, state, county, municipal, local or foreign government, or any political subdivision, court, body, agency or regulatory
authority thereof, and any Person exercising executive, legislative, judicial, regulatory, taxing or administrative functions of or pertaining to any of the foregoing. 
 (ii) “Law” means any federal, state, local, national or foreign law, statute, code, ordinance, rule, regulation, order, judgment, writ, stipulation, award, injunction, decree or
arbitration award or finding. 
 (b) The Company has not committed any act, made any statement or failed to make any
statement that would reasonably be expected to provide a basis for the FDA or any other Governmental Entity to invoke its policy with respect to “Fraud, Untrue Statements of Material Facts, Bribery, and Illegal Gratuities”, or similar
policies, set forth in any applicable Laws. Neither the Company, nor, to the knowledge of the Company, any of its officers, key employees or agents has been convicted of any crime or engaged in any conduct that has resulted, or would reasonably be
expected to result, in debarment under applicable Law, including, without limitation, 21 U.S.C. Section 335a. No claims, actions, proceedings or investigations that would reasonably be expected to result in such a material debarment or
exclusion are pending, or to the knowledge of the Company, threatened, against the Company or any of its respective officers, employees or agents. 
 (c) Each of the Company and, to its knowledge, its directors, officers, employees, and agents (while acting in such capacity) is, and at all times has been, in material compliance with all health
care Laws applicable to the Company or by which any of its properties, businesses, products or other assets is bound or affected, including, without limitation, the federal Anti-kickback Statute (42 U.S.C. § 1320a-7b(b)), the Anti-Inducement
Law (42 U.S.C. § 1320a-7a(a)(5)), the civil False Claims Act (31 U.S.C. §§ 3729 et seq.), the administrative False Claims Law (42 U.S.C. § 1320a-7b(a)), the Health Insurance Portability and Accountability Act of 1996 (42
U.S.C. § 1320d et seq.), the exclusion laws (42 U.S.C. § 1320a-7), the Food Drug and Cosmetic Act (21 U.S.C. §§ 301 et seq.) (collectively, “Health Care Laws”). The Company has not received any notification,
correspondence or any other written or oral communication from any Governmental Entity, including, without limitation, the FDA, the Centers for Medicare and Medicaid Services, and the Department of Health and Human Services Office of Inspector
General, of potential or actual material non-compliance by, or liability of, the Company under any Health Care Laws. 

 (d) The Company is not a party to any corporate integrity agreements, monitoring
agreements, consent decrees, settlement orders, or similar agreements with or imposed by any Governmental Entity. 
 3.16
Application of Takeover Protections. The issuance of the shares hereunder and Intrexon’s ownership thereof is not prohibited by the business combination statutes of the state of Florida. The Company has not adopted any stockholder rights
plan, “poison pill” or similar arrangement that would trigger any right, obligation or event as a result of the issuance of such shares and Intrexon’s ownership of such shares and there are no similar anti-takeover provisions under
the Company’s charter documents. 
 3.17 Listing and Maintenance Requirements. The Company is in compliance
with the requirements of the OTC Bulletin Board for continued listing of the Common Stock thereon. The issuance and sale of the shares hereunder does not contravene the rules and regulations of the OTC Bulletin Board. 

3.18 Private Placement. Neither the Company nor its Affiliates, nor any Person acting on its or their behalf, (i) has
engaged in any form of general solicitation or general advertising (within the meaning of Regulation D under the Securities Act) in connection with the offer or sale of the shares hereunder, (ii) has, directly or indirectly, made any offers or
sales of any security or solicited any offers to buy any security, under any circumstances that would require registration of the sale and issuance by the Company of the shares under the Securities Act or (iii) has issued any shares of Common
Stock or shares of any series of preferred stock or other securities or instruments convertible into, exchangeable for or otherwise entitling the holder thereof to acquire shares of Common Stock which would be integrated with the sale of the shares
to Intrexon for purposes of the Securities Act or of any applicable stockholder approval provisions, including, without limitation, under the rules and regulations of any exchange or automated quotation system on which any of the securities of the
Company are listed or designated, nor will the Company or any of its subsidiaries or affiliates take any action or steps that would require registration of any of the shares under the Securities Act or cause the offering of the shares to be
integrated with other offerings. Assuming the accuracy of the representations and warranties of Intrexon, the offer and issuance of the shares by the Company to Intrexon pursuant to this Agreement will be exempt from the registration requirements of
the Securities Act. 
 3.19 No Manipulation of Stock. The Company has not taken, and has no plans to take,
in violation of applicable law, any action outside the ordinary course of business designed to, or that might reasonably be expected to, cause or result in unlawful manipulation of the price of the Common Stock. 

3.20 Brokers. Other than Griffin Securities, Inc., neither the Company nor any of the officers, directors or employees of
the Company has employed any broker or finder in connection with the transaction contemplated by this Agreement. The Company shall indemnify Intrexon from and against any broker’s, finder’s or agent’s fees for which the Company is
responsible. 
 SECTION 4. REPRESENTATIONS, WARRANTIES AND
COVENANTS OF INTREXON. 
 4.1 Purchaser
Sophistication. Intrexon represents and warrants to, and covenants with, the Company that Intrexon (a) is knowledgeable, sophisticated and experienced in making, and is qualified to make decisions with respect to, investments in shares
presenting an investment decision like that involved in the acceptance of the shares pursuant hereto, including investments in securities issued by the Company and investments in comparable companies, and has requested, received, reviewed and
considered all information it deemed relevant in making an informed decision to purchase the shares, (b) Intrexon, in connection with its decision to purchase the shares, relied only upon the SEC Documents, other publicly available information,
and the representations and warranties of the Company contained herein. Intrexon is an “accredited investor” pursuant to Rule 501 of Regulation D under the Securities Act, (c) Intrexon is acquiring the shares for its own account for
investment only and with no present intention of distributing any of such shares or any arrangement or understanding with any other persons regarding the distribution of such shares; (d) Intrexon has not been organized, reorganized or
recapitalized specifically for the purpose of investing in the shares; (e) Intrexon will not, directly or indirectly, offer, sell, pledge, transfer or otherwise dispose of (or solicit any offers to buy, purchase or otherwise acquire to take a
pledge of) any of the shares except in compliance with the Securities Act and applicable state securities laws, (f) Intrexon understands that the shares are being offered and sold to it in reliance upon specific exemptions from the registration
requirements of the Securities Act and state securities laws, and that the Company is 

 
relying upon the truth and accuracy of, and Intrexon’s compliance with, the representations, warranties, agreements, acknowledgments and understandings of Intrexon set forth herein in order
to determine the availability of such exemptions and the eligibility of Intrexon to acquire the shares, (g) Intrexon understands that its investment in the shares involves a significant degree of risk, including a risk of total loss of
Intrexon’s investment (provided that such acknowledgment in no way diminishes the representations, warranties and covenants made by the Company hereunder) and (h) Intrexon understands that no United States federal or state agency or any
other government or governmental agency has passed upon or made any recommendation or endorsement of the shares. 
 4.2
Authorization and Power. Intrexon has the requisite power and authority to enter into and perform this Agreement. The execution, delivery and performance of this Agreement by Intrexon and the consummation by it of the transactions
contemplated hereby have been duly authorized by all necessary corporate action, and no further consent or authorization of Intrexon or its board of directors or stockholders is required. When executed and delivered by Intrexon, this Agreement shall
constitute a valid and binding obligation of Intrexon enforceable against Intrexon in accordance with its terms, except as such enforceability may be limited by applicable bankruptcy, insolvency, reorganization, moratorium, liquidation,
conservatorship, receivership or similar laws relating to, or affecting generally the enforcement of, creditor’s rights and remedies or by other equitable principles of general application. 

4.3 No Conflict. The execution, delivery and performance of this Agreement by Intrexon and the consummation by Intrexon of
the transactions contemplated hereby do not and will not (i) violate any provision of Intrexon’s charter or organizational documents, (ii) conflict with, or constitute a default (or an event which with notice or lapse of time or both
would become a default) under, or give to others any rights of termination, amendment, acceleration or cancellation of, any agreement, mortgage, deed of trust, indenture, note, bond, license, lease agreement, instrument or obligation to which
Intrexon is a party or by which Intrexon’s properties or assets are bound, or (iii) result in a violation of any federal, state, local or foreign statute, rule, regulation, order, judgment or decree (including federal and state securities
laws and regulations) applicable to Intrexon or by which any property or asset of Intrexon are bound or affected, except, in all cases, other than violations (with respect to federal and state securities laws) above, for such conflicts, defaults,
terminations, amendments, acceleration, cancellations and violations as would not, individually or in the aggregate, materially and adversely affect Intrexon’s ability to perform its obligations under the Agreement. 

4.4 Restricted Shares. Intrexon acknowledges that the shares when issued shall be restricted securities and must be held
indefinitely unless subsequently registered under the Securities Act or the Company receives an opinion of counsel reasonably satisfactory to the Company that such registration is not required. Intrexon is aware of the provisions of Rule 144
promulgated under the Securities Act which permit limited resale of stock purchased in a private placement subject to the satisfaction of certain conditions, including, among other things, the existence of a public market for the stock, the
availability of certain current public information about the Company, the resale occurring not less than one year after a party has purchased and paid for the stock to be sold, the sale being through a “broker’s transaction” or a
transaction directly with a “market maker” and the number of shares of the stock being sold during any three-month period not exceeding specified limitations. Intrexon further acknowledges and understands that the Company may not be
satisfying the current public information requirement of Rule 144 at the time Intrexon wishes to sell the shares and, if so, Intrexon would be precluded from selling the shares under Rule 144 even if the one year minimum holding period has been
satisfied. 
 4.5 Ownership of Common Stock. As of the date hereof, excluding the Technology Access Fee Shares,
Intrexon and its Affiliates beneficially own no shares of Common Stock of the Company. 
 4.6 Stock Legends.
Intrexon acknowledges that certificates evidencing the Technology Access Fee Shares shall bear a restrictive legend in substantially the following form (and including related stock transfer instructions and record notations): 

4.7 THESE SECURITIES HAVE NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY
STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE
SECURITIES ACT OR PURSUANT TO AN 

 
AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS OR BLUE SKY LAWS AS
EVIDENCED BY A LEGAL OPINION OF COUNSEL REASONABLY SATISFACTORY TO THE COMPANY. 
 4.8 Brokers. Neither Intrexon
nor any of the officers, directors or employees of Intrexon has employed any broker or finder in connection with the transaction contemplated by this Agreement. Intrexon shall indemnify the Company from and against any broker’s, finder’s
or agent’s fees for which Intrexon is responsible. 
 SECTION 5. REGISTRATION RIGHTS.

 5.1 Piggyback Registration Rights. If, at any time, the Company proposes to file a registration statement
under the Securities Act, other than a registration relating solely to employee benefit plans or Rule 145 transactions, with respect to an underwritten offering for its own account of any class of securities of the Company (a “Registration
Statement”), then each such time, the Company shall give written notice of such intention to file a Registration Statement (a “Piggyback Notice”) to Intrexon at least five (5) days before the anticipated filing
date. The Piggyback Notice shall describe the number of shares to be registered and the intended method of distribution and offer Intrexon the opportunity to register pursuant to such Registration Statement such shares held by Intrexon (the
“Registrable Shares”) as Intrexon may request in writing to the Company within five (5) days after the date Intrexon first received the Piggyback Notice (a “Piggyback Registration”). The Piggyback Registration
rights shall be subject ratably to potential underwriter’s limitations set forth herein. The Company shall take all reasonable steps to include in the Registration Statement the Registrable Shares which the Company has been so requested to
register by Intrexon. The Company shall be entitled to suspend or withdraw a Registration Statement prior to its becoming effective. If the managing underwriter with respect to such an offering advises the Company in writing that the inclusion of
all or any portion of the Registrable Shares which Intrexon has requested to be included in the Registration Statement would materially jeopardize the success of the offering, then the Company shall be required to include in the underwriting only
that number of Registrable Shares which the underwriter advises the Company in writing may be sold without materially jeopardizing the offering. If Intrexon disapproves of the terms of any such underwriting may elect to withdraw its Registrable
Shares from it by written notice to the Company and the underwriter. Intrexon also agrees to be subject to any lock-up agreements reasonably requested by a managing underwriter so long as the Company shares held by the Company’s largest
shareholder are also subject to a similar lock-up agreement. The Company shall not grant registration rights to any other holder or prospective holder of its securities in connection with a private placement of the Company’s securities unless,
(i) all shares held by Intrexon are, at the time of such private placement, included on a Registration Statement, or (ii) the Company agrees, in connection with such private placement, to grant Intrexon the right to include on the
Registration Statement a number of Intrexon’s Registrable Shares equal to one half of the number of shares to be registered on behalf of the other holder or prospective holder. 

5.2 Registration Expenses. All reasonable fees and expenses incident to the performance of or compliance with this
Agreement by the Company, except as and to the extent specified in this Section 5, shall be borne by the Company whether or not the Registration Statement is filed or becomes effective and whether or not any shares are sold pursuant to the
Registration Statement. The fees and expenses referred to in the foregoing sentence shall include, without limitation, (i) all registration and filing fees (including, without limitation, fees and expenses (A) with respect to filings
required to be made with each securities exchange or market on which shares are listed, (B) with respect to filings required to be made with the Financial Industry Regulatory Authority and (C) in compliance with state securities or Blue
Sky laws, (ii) messenger, telephone and delivery expenses, (iii) fees and disbursements of counsel for the Company, (iv) Securities Act liability insurance, if the Company so desires such insurance, and (v) fees and expenses of
all other persons or entities retained by the Company in connection with the consummation of the transactions contemplated by this Section 5, including, without limitation, the Company’s independent public accountants. 

5.3 Indemnification by the Company. The Company shall, notwithstanding any termination of this Agreement, indemnify and
hold harmless Intrexon, its permitted assignees, officers, directors, agents, Affiliates and employees, to the fullest extent permitted by applicable law, from and against any and all claims, losses, damages, liabilities, penalties, judgments, costs
and expenses (including, without limitation, reasonable attorneys’ fees and 

 
expenses) (collectively, “Losses”), arising out of or relating to any untrue or alleged untrue statement of a material fact contained in a Registration Statement or arising out of or
relating to any omission or alleged omission of a material fact required to be stated therein or necessary to make the statements therein (in the case of any prospectus or form of prospectus or supplement thereto, in the light of the circumstances
under which they were made) not misleading, except (i) to the extent that such untrue statements or omissions are based upon information furnished to the Company by Intrexon expressly for use in the Registration Statement; (ii) as a result
of the failure of such indemnitee to deliver a prospectus, as amended or supplemented, to a purchaser in connection with an offer or sale; or (iii) the use by the indemnitee of an outdated or defective prospectus after the Company has notified
Intrexon in writing that the prospectus is outdated or defective, but only if and to the extent that following such receipt the misstatement or omission giving rise to such Loss would have been corrected; provided, however, that the indemnity
agreement contained in this Section 5.3 shall not apply to amounts paid in settlement of any Losses if such settlement is effected without the prior written consent of the Company, which consent shall not be unreasonably withheld. 

5.4 Indemnification by Intrexon. Intrexon shall indemnify and hold harmless the Company, its directors, officers, agents
and employees to the fullest extent permitted by applicable law, from and against all Losses, as incurred, arising out of or relating to any untrue or alleged untrue statement of a material fact contained in a Registration Statement or arising out
of or relating to any omission or alleged omission of a material fact required to be stated therein or necessary to make the statements therein (in the case of any prospectus or supplement thereto, in the light of the circumstances under which they
were made) not misleading, to the extent that such untrue statement or omission is contained in or omitted from any information regarding Intrexon furnished in writing to the Company by Intrexon expressly for use in therein, and that such
information was reasonably relied upon by the Company for use therein, or to the extent that such information relates to Intrexon or Intrexon’s proposed method of distribution of shares and was furnished in writing by Intrexon expressly for use
therein. Notwithstanding anything to the contrary contained herein, in no event shall the liability of Intrexon under this Section 5.4 exceed the net proceeds to Intrexon as a result of the sale of shares pursuant to a Registration Statement in
connection with which the untrue or alleged untrue statement or material omission was provided. 
 SECTION 6.
SURVIVAL OF REPRESENTATIONS, WARRANTIES AND AGREEMENTS. 
 Notwithstanding any investigation made by any party to this Agreement, all representations and warranties made by the Company and Intrexon herein shall survive the execution of this Agreement and the
issuance to Intrexon of the Technology Access Fee Shares and shall terminate eighteen (18) months after the Technology Access Fee Shares Closing, provided, however, that the representations and warranties in Sections 3.1, 3.2 and 3.3
shall survive for so long as Intrexon continues to hold any of the Technology Access Fee Shares sold hereunder. No claim may be asserted against either party for breach of any representation or warranty contained herein, unless written notice of
such claim is received by such party describing in reasonable detail and to the extent available the facts and circumstances with respect to the subject matter of such claim on or prior to the date on which the representation or warranty on which
such claim is based ceases to survive as set forth above. In no event shall any party be liable to the other party for any punitive, incidental, consequential, special or indirect damages, including loss of future revenue or income, loss of business
reputation or opportunity relating to the breach or alleged breach of any representation or warranty in this Agreement. 

SECTION 7. COVENANTS. 

7.1 Notifications. 
 (a) During the period prior to the Technology Access Fee Shares Closing, the Company will promptly advise Intrexon in writing of (i) any Material Adverse Effect, or (ii) any notice or
other communication from any third person or entity alleging that the consent of the third person is required in connection with the transactions contemplated by this Agreement. 

(b) Information received by Intrexon pursuant to this Section 7.1 shall be considered “Confidential Information”
as such term is defined in the Channel Agreement and Intrexon agrees to treat such information in accordance with the provisions of Article 7 of the Channel Agreement. 

 7.2 Standstill Provision. 

(a) Intrexon hereby agrees that, for a period of three years from the date hereof, unless specifically invited in writing by the
Company to do so, neither Intrexon nor any of its Affiliates will, or will cause or knowingly permit any of its or their directors, officers, employees, investment bankers, attorneys, accountants or other advisors or representatives to, in any
manner, directly or indirectly: 
 (i) effect or seek, initiate, offer or propose (whether publicly or otherwise) to
effect, or cause or participate in or in any way advise or, assist any other person to effect or seek, initiate, offer or propose (whether publicly or otherwise) to effect or cause or participate in, any acquisition of any securities (or beneficial
ownership thereof) or assets of the Company; any tender or exchange offer, merger, consolidation or other business combination involving the Company; any recapitalization, restructuring, liquidation, dissolution or other extraordinary transaction
with respect to the Company; or any “solicitation” of “proxies” (as such terms are used in the proxy rules of the Commission) or consents to vote any voting securities of the Company; 

(ii) form, join or in any way participate in a “group” (as defined under the Exchange Act, hereafter a
“Group”) with respect to any securities of the Company; 
 (iii) otherwise act, alone or in concert with
others, to seek to control or influence the management, board of directors, or policies of the Company (except as contemplated by Section 7.4 of this Agreement); 
 (iv) take any action which could reasonably be expected to force the Company to make a public announcement regarding any of the types of matters set forth in this Section 7.2; or 

(v) enter into any agreements, discussions or arrangements with any third party with respect to any of the foregoing. 

(b) Notwithstanding the foregoing, the Company hereby agrees that the provisions of this Section 7.2 shall not apply to the
following: 
 (i) the purchase by Intrexon and/or its Affiliates after the date hereof (and not pursuant to this
Agreement) of up to an aggregate number of shares of Common Stock that does not exceed 10% of the number of shares of Common Stock then issued and outstanding; 
 (ii) the exercise by Intrexon and/or its Affiliates, if applicable, of any voting rights available to Company stockholders generally pursuant to any transaction described Section 7.2(a)(i)
above, provided that Intrexon has not then either directly, indirectly, or as a member of a Group made, effected, initiated or caused such transaction to occur or otherwise violated this Section 7.2; 

(iii) the exercise by Intrexon and/or its Affiliates, if applicable, of any voting rights generally available to it or them as
non-Affiliate security holders of a third party that is a participant in an action or transaction described in Section 7.2(a)(i) above, provided that Intrexon has not then either directly, indirectly, or as a member of a Group made, effected,
initiated or caused such action or transaction to occur or otherwise violated this Section 7.2; 
 (iv) any
activity by Intrexon after the Company has made any public announcement of its intent to solicit or engage in any transaction which would result in a Company Sale; 
 (v) making any communication to Company executive management on a confidential basis solely that Intrexon would be interested in engaging in discussions with the Company that could result in a
negotiated transaction described in Section 7.2(a)(i) so long as Intrexon does not propose any such transaction or discuss or refer to potential terms thereof without the Company’s prior consent; and 

 (vi) Intrexon exercising its Equity Purchase Participation Right in accord with
Section 8. 
 (c) Subject to Section 11.13, Intrexon’s rights and the Company’s obligations under
this Section 7.2 shall terminate upon the termination of the Channel Agreement. 
 7.3 Intrexon Proposals.
Notwithstanding any of the foregoing provisions of Section 7.2, the Company further agrees that nothing herein shall limit the ability of Intrexon to confidentially propose to the executive management of the Company and its board of directors,
and/or advocate for, any transaction between the Company and any third party unaffiliated with Intrexon or its Affiliates. 

7.4 Further Assurances. Each of the Company and Intrexon shall do and perform, or cause to be done and performed, all such
further acts and things, and shall execute and deliver all such other agreements, certificates, instruments and documents, as each other party may reasonably request in order to carry out the intent and accomplish the purposes of this Agreement, the
Channel Agreement and the consummation of the transactions contemplated thereby. 
 SECTION 8. EQUITY
PURCHASE PARTICIPATION RIGHT 
 8.1 Intrexon Equity Purchase
Participation Right. Intrexon shall be entitled to, at its election, participate in each Qualified Financing (as hereinafter defined) conducted by the Company and may purchase as part of, or in connection with, such Qualified Financing an amount
of Common Stock or other of the Company’s securities equal to up to 30% of the number of shares of Common Stock (or other of the Company’s securities) issued and sold by the Company in the Qualified Financing (excluding the securities sold
pursuant to this Section 8.1) (collectively, the “Equity Purchase Participation Right”). For the purposes of this Section 8, a “Qualified Financing” shall mean a sale by the Company of Common Stock, or
equity securities convertible into Common Stock, in a public or private offering, raising gross cash proceeds of at least $1,000,000 where the shares sold are either registered under the Securities Act on issuance, or the Company agrees to register
such shares following the issuance of such shares. The price per share paid by Intrexon in any such Qualified Financing shall be the same as that paid by the other investors in such Qualified Financing, and upon the exercise of the Equity Purchase
Participation Right Intrexon shall receive securities of the same type and with the same rights, preferences and privileges as the other investors in such Qualified Financing, including, for example, any warrant coverage, subject to the execution by
Intrexon of the investment documents entered into by the other investors in the Qualified Financing. 
 In the event that the
Company intends to conduct a Qualified Financing: 
 (a) Upon receipt of written notice from the Company that it intends
to conduct a Qualified Financing, Intrexon shall, within ten (10) days of receipt of such documents, notify the Company as to whether Intrexon wishes to participate in the Qualified Financing. Upon such election, and subject to
Section 8.1(b), the Company shall permit Intrexon to participate in such offering in the amount elected by Intrexon in accordance with the preceding sentence. 
 (b) If counsel to the Company or counsel to any underwriter in a public offering that is a Qualified Financing advises the Company that Intrexon’s inclusion is not permissible under and in
compliance with applicable securities laws (including without limitation Section 6 of the Securities Act), the offering and sale of securities to Intrexon pursuant to this Section 8.1 shall be made by the Company in a concurrent private
placement and not in such public offering. In any such private placement: (i) the offer of the securities in such private placement shall be made on the same terms and conditions as the offer of the securities in the public offering,
(ii) the closing of the private placement shall occur concurrently with the closing of the Qualified Financing, and (iii) the Company shall provide registration rights similar to those provided in Section 5.1 of this Agreement with
respect to the securities purchased in the private placement. 

 SECTION 9. CONDITIONS TO
CLOSING. 
 9.1 The obligation hereunder of the Company to issue shares to
Intrexon at each Closing is subject to the satisfaction or waiver, at or before the Closing of the conditions set forth below. These conditions are for the Company’s sole benefit and may be waived by the Company at any time in its sole
discretion. 
 (a) Accuracy of Intrexon’s Representations and Warranties. The representations and warranties
of Intrexon shall be true and correct as of the date when made and as of the Closing Date as though made at that time, except for representations and warranties that are expressly made as of a particular date, which shall be true and correct as of
such date. 
 (b) Performance by Intrexon. Intrexon shall have performed, satisfied and complied in all material
respects with all covenants, agreements and conditions required by this Agreement and the Channel Agreement to be performed, satisfied or complied by Intrexon at or prior to the Closing Date. 

(c) Channel Partnership Agreement. The Channel Agreement shall have been entered into by the Company and Intrexon and
shall be in full force and effect. 
 (d) No Injunction. No statute, rule, regulation, executive order, decree,
ruling or injunction shall have been enacted, entered, promulgated or endorsed by any court or governmental authority of competent jurisdiction which prohibits the consummation of any of the transactions contemplated by this Agreement. 

(e) No Proceedings or Litigation. No action, suit or proceeding before any arbitrator or any governmental authority shall
have been commenced, and no investigation by any governmental authority shall have been threatened in writing against Intrexon or any of the officers, directors or Affiliates of Intrexon seeking to restrain, prevent or change the transactions
contemplated by this Agreement, the Channel Agreement or seeking damages in connection with such transactions. 
 9.2 The
obligation hereunder of Intrexon to receive Shares and consummate the transactions contemplated by this Agreement is subject to the satisfaction or waiver, at or before each Closing, of each of the conditions set forth below. These conditions are
for Intrexon’s sole benefit and may be waived by Intrexon at any time in its sole discretion. 
 (a) Accuracy of
the Company’s Representations and Warranties. Each of the representations and warranties of the Company in this Agreement shall be true and correct as of the Closing Date, except for representations and warranties that speak as of a
particular date, which shall be true and correct as of such date. 
 (b) Performance by the Company. The Company
shall have performed, satisfied and complied in all material respects with all covenants, agreements and conditions required by this Agreement and the Channel Agreement to be performed, satisfied or complied with by the Company at or prior to the
Closing Date. 
 (c) Channel Partnership Agreement. The Channel Agreement shall have been entered into by the
Company and Intrexon and shall be in full force and effect. 
 (d) No Injunction. No statute, rule, regulation,
executive order, decree, ruling or injunction shall have been enacted, entered, promulgated or endorsed by any court or governmental authority of competent jurisdiction which prohibits the consummation of any of the transactions contemplated by this
Agreement or the Channel Agreement. 
 (e) No Proceedings or Litigation. No action, suit or proceeding before any
arbitrator or any governmental authority shall have been commenced, and no investigation by any governmental authority shall have been threatened in writing against the Company or any of the officers, directors or Affiliates of the Company seeking
to restrain, prevent or change the transactions contemplated by this Agreement, the Channel Agreement or seeking damages in connection with such transactions. 

 (f) Opinion. Counsel for the Company shall have delivered to Intrexon an
opinion letter containing legal opinions in a form reasonably acceptable to Intrexon. 
 (g) No Material Adverse
Effect. Since the date of this Agreement, there shall not have occurred any Material Adverse Effect. 
 SECTION 10.
NOTICES. 
 All notices or other communications which are required or permitted hereunder shall be in
writing and addressed as follows: 
  

			
	If to the Company:	  	Oragenics, Inc.
		  	3000 Bayport Drive, Suite 685,
		  	Tampa, FL 33607
		  	Attention: Chief Executive Officer
		  	Fax No.: (813) 286-7904
		
	If to Intrexon:	  	Intrexon Corporation
		  	20358 Seneca Meadows Parkway
		  	Germantown, MD 20876
		  	Attention: Legal Department
		  	Fax No.: (301) 556-9902

 or to such other address as the party to whom notice is to be given may have furnished to the other party in writing in
accordance herewith. Any such communication shall be deemed to have been given when delivered if personally delivered or sent by facsimile (provided that the party providing such notice promptly confirms receipt of such transmission with the other
party by telephone), on the business day after dispatch if sent by a nationally-recognized overnight courier and on the third business day following the date of mailing if sent by certified mail, postage prepaid, return receipt requested.

 SECTION 11. MISCELLANEOUS. 

11.1 Fees and Expenses. Each party shall pay the fees and expenses of its advisors, counsel, accountants and other experts,
if any, and all other expenses, incurred by such party incident to the negotiation, preparation, execution, delivery and performance of this Agreement. 
 11.2 Waivers and Amendments. Neither this Agreement nor any provision hereof may be changed, waived, discharged, terminated, modified or amended except upon the written consent of the
parties hereto. 
 11.3 Headings. The headings of the various sections of this Agreement have been inserted for
convenience of reference only and shall not be deemed to be part of this Agreement. 
 11.4 Severability. If any
provision hereof should be held invalid, illegal or unenforceable in any respect, then, to the fullest extent permitted by law, (a) all other provisions hereof shall remain in full force and effect and shall be liberally construed in order to
carry out the intentions of the Parties as nearly as may be possible and (b) the parties shall use their best efforts to replace the invalid, illegal or unenforceable provision(s) with valid, legal and enforceable provision(s) which, insofar as
practical, implement the purposes of such provision(s) in this Agreement. 
 11.5 Governing Law. This Agreement
shall be governed by and construed in accordance with the laws of the State of Delaware as applied to contracts entered into and performed entirely in the State of Delaware by Delaware residents, without regard to conflicts of law principles.

 11.6 Counterparts. This Agreement may be executed in two or more counterparts (including by facsimile, PDF, or
other means of electronic communication), each of which shall constitute an original, but all of which, when taken together, shall constitute but one instrument, and shall become effective when one or more counterparts have been signed by each party
hereto and delivered to the other parties. 

 11.7 Successors and Assigns. Except as otherwise expressly provided herein,
the provisions hereof shall inure to the benefit of, and be binding upon, the successors, assigns, heirs, executors and administrators of the parties hereto, provided that Intrexon shall not assign its rights or obligations hereunder unless Intrexon
assigns such rights in whole and not in part to an assignee of such rights and obligations which shall agree in writing with the Company to be bound by this Agreement and that Intrexon’s rights under Sections 7.1 and 7.2 and obligations under
Section 8 shall not be assignable. 
 11.8 No Third Party Beneficiaries. This Agreement is intended for the
benefit of the parties hereto and their respective permitted successors and assigns and is not for the benefit of, nor may any provision hereof be enforced by, any other person. 

11.9 Expenses. Each party shall pay all costs and expenses that it incurs with respect to the negotiation, execution,
delivery and performance of this Agreement. 
 11.10 Entire Agreement. This Agreement (including the Schedule of
Exceptions), the Channel Agreement and other documents executed and delivered pursuant hereto and thereto, including the exhibits, constitute the full and entire understanding and agreement between the parties with regard to the subjects hereof and
thereof. 
 11.11 Publicity. Except as otherwise provided herein, no party shall issue any press releases or
otherwise make any public statement with respect to the transactions contemplated by this Agreement without the prior written consent of the other party, except as may be required by applicable law or regulations, in which case such party shall
provide the other parties with reasonable notice of such publicity and/or opportunity to review such disclosure. The Company shall issue a press release announcing the transaction contemplated by this Agreement and the Channel Agreement prior to the
opening of the financial markets in New York City on the business day immediately following the date hereof. Such press release shall be substantially in the form mutually agreed to by the parties. 

11.12 Waiver of Rule of Construction. Each Party has had the opportunity to consult with counsel in connection with
the review, drafting and negotiation of this Agreement. Accordingly, the rule of construction that any ambiguity in this Agreement shall be construed against the drafting Party shall not apply. 

11.13 Company Sale. For purposes of this Agreement, a “Company Sale” shall mean the sale of the
Company, whether in a single transaction or in a series of related transactions that are consummated contemporaneously (or consummated pursuant to contemporaneous agreements), to one or more unaffiliated third parties on an
arm’s-length basis, pursuant to which such unaffiliated third party or parties acquires (i) (whether by merger, consolidation, sale or transfer of capital stock, recapitalization, or otherwise) more than fifty percent
(50%) of the Company’s capital stock or (ii) all or substantially all of the assets of the Company determined on a consolidated basis.
 [Remainder of page intentionally left blank.] 

 IN WITNESS WHEREOF, the
parties hereto have caused this Stock Issuance Agreement to be executed by their duly authorized representatives as of the day and year first above written. 

 

			
	ORAGENICS, INC.
		
	By:	 	 /s/ John N. Bonfiglio

	Name:	 	 John N. Bonfiglio

	Title:	 	 President and CEO

	
	INTREXON CORPORATION
		
	By:	 	 /s/ Jayson Rieger

	Name:	 	 Jayson Rieger

	Title:	 	 SVP, President HTD

									
	 SECTION 1.
	 		  	AUTHORIZATION OF ISSUANCE OF SHARES	  	 	1	  
				
	 1.1
	 		  	 Technology Access Fee Shares
	  	 	1	  
				
	 1.2
	 		  	 Milestones
	  	 	1	  
				
	 1.3
	 		  	 Company Sale
	  	 	2	  
				
	 1.4
	 		  	 Capital Adjustments
	  	 	3	  
				
	 SECTION 2.
	 		  	CLOSING AND DELIVERY	  	 	3	  
				
	 2.1
	 		  	 Issuance of Technology Access Fee Shares
	  	 	3	  
				
	 2.2
	 		  	 Closings
	  	 	4	  
				
	 2.3
	 		  	 Delivery of the Shares
	  	 	4	  
				
	 SECTION 3.
	 		  	REPRESENTATIONS AND WARRANTIES OF THE COMPANY	  	 	4	  
				
	 3.1
	 		  	 Organization, Good Standing and Power
	  	 	4	  
				
	 3.2
	 		  	 Authorization; Enforcement
	  	 	5	  
				
	 3.3
	 		  	 Issuance of Shares
	  	 	5	  
				
	 3.4
	 		  	 No Conflicts; Governmental Approvals
	  	 	5	  
				
	 3.5
	 		  	 Commission Documents, Financial Statements
	  	 	6	  
				
	 3.6
	 		  	 Accountants
	  	 	6	  
				
	 3.7
	 		  	 Internal Controls
	  	 	6	  
				
	 3.8
	 		  	 Disclosure Controls
	  	 	6	  
				
	 3.9
	 		  	 No Material Adverse Change
	  	 	7	  
				
	 3.10
	 		  	 No Undisclosed Events or Circumstances
	  	 	7	  
				
	 3.11
	 		  	 Litigation
	  	 	7	  
				
	 3.12
	 		  	 Compliance
	  	 	7	  
				
	 3.13
	 		  	 Intellectual Property
	  	 	7	  
				
	 3.14
	 		  	 FDA Compliance
	  	 	8	  
				
	 3.15
	 		  	 General Healthcare Regulatory Compliance
	  	 	9	  
				
	 3.16
	 		  	 Application of Takeover Protections
	  	 	10	  
				
	 3.17
	 		  	 Listing and Maintenance Requirements
	  	 	10	  
				
	 3.18
	 		  	 Private Placement
	  	 	10	  
				
	 3.19
	 		  	 No Manipulation of Stock
	  	 	11	  
				
	 3.20
	 		  	 Brokers
	  	 	11	  
				
	 SECTION 4.
	 		  	REPRESENTATIONS, WARRANTIES AND COVENANTS OF INTREXON	  	 	11	  
				
	 4.1
	 		  	 Purchaser Sophistication
	  	 	11	  
				
	 4.2
	 		  	 Authorization and Power
	  	 	12	  
				
	 4.3
	 		  	 No Conflict
	  	 	12	  
				
	 4.4
	 		  	 Restricted Shares
	  	 	12	  
				
	 4.5
	 		  	 Ownership of Common Stock
	  	 	13	  

  
 1 

									
	 4.6
	 		  	 Stock Legends
	  	 	13	  
				
	 4.7
	 		  	 Brokers
	  	 	13	  
				
	 SECTION 5.
	 		  	REGISTRATION RIGHTS	  	 	13	  
				
	 5.1
	 		  	 Piggyback Registration Rights
	  	 	13	  
				
	 5.2
	 		  	 Registration Expenses
	  	 	14	  
				
	 5.3
	 		  	 Indemnification by the Company
	  	 	14	  
				
	 5.4
	 		  	 Indemnification by Intrexon
	  	 	15	  
				
	 SECTION 6.
	 		  	SURVIVAL OF REPRESENTATIONS, WARRANTIES AND AGREEMENTS	  	 	15	  
				
	 SECTION 7.
	 		  	COVENANTS	  	 	15	  
				
	 7.1
	 		  	 Notifications
	  	 	15	  
				
	 7.2
	 		  	 Standstill Provision
	  	 	16	  
				
	 7.3
	 		  	 Intrexon Proposals
	  	 	17	  
				
	 7.4
	 		  	 Further Assurances
	  	 	17	  
				
	 SECTION 8.
	 		  	EQUITY PURCHASE PARTICIPATION RIGHT	  	 	17	  
				
	 8.1
	 		  	 Intrexon Equity Purchase Participation Right
	  	 	17	  
				
	 SECTION 9.
	 		  	CONDITIONS TO CLOSING	  	 	18	  
				
	 9.1
	 		  	 Company Conditions to Closing
	  	 	18	  
				
		 	 (a)
	  	 Accuracy of Intrexon’s Representations and Warranties
	  	 	18	  
				
		 	 (b)
	  	 Performance by Intrexon
	  	 	18	  
				
		 	 (c)
	  	 Channel Partnership Agreement
	  	 	19	  
				
		 	 (d)
	  	 No Injunction
	  	 	19	  
				
		 	 (e)
	  	 No Proceedings or Litigation
	  	 	19	  
				
	 9.2
	 		  	 Intrexon Conditions to Closing
	  	 	19	  
				
		 	 (a)
	  	 Accuracy of the Company’s Representations and Warranties
	  	 	19	  
				
		 	 (b)
	  	 Performance by the Company
	  	 	19	  
				
		 	 (c)
	  	 Channel Partnership Agreement
	  	 	19	  
				
		 	 (d)
	  	 No Injunction
	  	 	19	  
				
		 	 (e)
	  	 No Proceedings or Litigation
	  	 	19	  
				
		 	 (f)
	  	 Opinion
	  	 	19	  
				
		 	 (g)
	  	 No Material Adverse Effect
	  	 	20	  
				
	 SECTION 10.
	 		  	NOTICES	  	 	20	  
				
	 SECTION 11.
	 		  	MISCELLANEOUS	  	 	20	  
				
	 11.1
	 		  	 Fees and Expenses
	  	 	20	  
				
	 11.2
	 		  	 Waivers and Amendments
	  	 	20	  
				
	 11.3
	 		  	 Headings
	  	 	20	  
				
	 11.4
	 		  	 Severability
	  	 	20	  

									
	 11.5
	 		  	 Governing Law
	  	 	21	  
				
	 11.6
	 		  	 Counterparts
	  	 	21	  
				
	 11.7
	 		  	 Successors and Assigns
	  	 	21	  
				
	 11.8
	 		  	 No Third Party Beneficiaries
	  	 	21	  
				
	 11.9
	 		  	 Expenses
	  	 	21	  
				
	 11.10
	 		  	 Entire Agreement
	  	 	21	  
				
	 11.11
	 		  	 Publicity
	  	 	21	  
				
	 11.12
	 		  	 Waiver of Rule of Construction
	  	 	21	  
				
	 11.13
	 		  	 Company Sale
	  	 	22First Amendment to Security Agreement

 Exhibit 10.3 
 FIRST AMENDMENT TO 
 SECURITY AGREEMENT 

This FIRST AMENDMENT TO SECURITY AGREEMENT (this “First Amendment”) is entered into as of June 5, 2012, by and
between ORAGENICS, INC., a Florida corporation located at 3000 Bayport Drive, Suite 685 Tampa, Florida 33607 (the “Company” or “Borrower”), and KOSKI FAMILY LIMITED PARTNERSHIP, a Texas limited partnership having a mailing
address of 3525 Turtle Creek Boulevard, Unit 19-B, Dallas, Texas 75219 (“KFLP” or “Lender”). 

RECITALS: 

WHEREAS, the Company entered into that certain Loan Agreement with the Lender on March 23, 2012 and issued a senior secured
convertible promissory note for borrowing up to $2.5 million (the “Loan”); 
 WHEREAS, in connection
with the Loan Agreement the Lender and the Company entered into a Security Agreement (the “Security Agreement”) of even date therewith which provided Lender with Collateral (as defined in the Security Agreement) to secure the Loan
contemplated by the Loan Agreement. 
 WHEREAS, the Security Agreement included as part of the Collateral securing the
Loan, certain in-licensed technologies licensed from the University of Florida Research Foundation (the “UFRF”), specifically the Company’s SMaRT Replacement Therapy and MU1140 technologies (the “UFRF In-Licensed
Technologies”); 
 WHEREAS, the Company and Intrexon Corporation (“Intrexon”) contemplate
entering into that certain Exclusive Channel Collaboration Agreement (“ECC”) and Stock Issuance Agreement (“SIA”) of even date herewith (the ECC and SIA are together the “Intrexon Agreements”); and

 WHEREAS, the Company and the KFLP desire to enter into the First Amendment to specifically release and exclude the
UFRF In-Licensed Technologies from the Collateral covered by the Security Agreement and add additional collateral in its place. 

NOW, THEREFORE, IN CONSIDERATION of the mutual covenants contained in this First Amendment, and for other good and valuable
consideration the receipt and adequacy of which are hereby acknowledged, the parties agree as follows: 
 1. The Recitals set
forth above are true and correct and are incorporated herein by reference. 
 2. The Security Agreement is hereby amended to
exclude and release the UFRF In-Licensed Technologies from the Collateral securing the loan made to the Company pursuant to the Loan Agreement. 
 3. The Security Agreement is hereby amended to include the Company’s Differentially Protected Orthogonal Lanthionine Technology (“DPOLT”) technology to the Collateral securing the
loan made to the Company pursuant to the Loan Agreement. 
 4. Upon either: (i) a default of the Loan Agreement or Security
Agreement or (ii) a breach of the ECC by the Company which gives rise to termination of the ECC by Intrexon, the Company hereby automatically, grants a worldwide, fully paid, non-exclusive, royalty-free sublicense to the UFRF In-Licensed
Technologies to the KFLP. 
 5. Upon the Company becoming aware of the existence of a breach of the ECC and possible termination
by Intrexon, it shall provide prompt written notice to the KLFP, which notice shall include the Company’s determination that it is unable or unwilling to cure the breach of the ECC (the “ECC Breach Notice”). In addition and as part of
the ECC Breach Notice the Company shall include an offer to the KFLP of the right to an assignment 

  
 1 

 
of all right title and interest in and to the Intrexon Agreements, subject to the KFLP’s agreement to assume the obligations under the Intrexon Agreements and subject to Intrexon’s
consent to the assignment upon the KFLP’s independent cure of the breach for its own sole benefit as part of this First Amendment to the Security Agreement. If the KFLP notifies the Company of its intent to cure the breach in order to avoid a
termination thereof by Intrexon, the Company shall cooperate and take all further actions reasonably necessary in furtherance of effecting the forgoing assignment. For the avoidance of doubt, the KFLP may, but it is not obligated to, proceed to cure
a breach of the ECC and receive the protective benefits provided herein. 
 6. All rights provided herein and pursuant to the
Security Agreement as amended hereby shall terminate if the Loan is converted in accordance with its terms.
 7. All of the
other terms of the Security Agreement not otherwise amended by the foregoing shall remain in full force and affect. 
 [REMAINDER
OF PAGE INTENTIONALLY LEFT BLANK 
 AND SIGNATURE PAGES FOLLOW] 

 IN WITNESS WHEREOF, the parties have executed this FIRST AMENDMENT TO SECURITY AGREEMENT on the date
first indicated above. 
  

			
	Borrower:
	
	Oragenics, Inc.
		
	By:	 	 /s/ John N. Bonfiglio

	Name:	 	 John N. Bonfiglio

	Title:	 	 President and Chief Executive Officer

	
	Lender:
	
	KOSKI FAMILY LIMITED PARTNERSHIP
		
	By:	 	 /s/ Christine L. Koski

	Name:	 	 Christine L. Koski

	Title:	 	 Managing General Partner

 [Signature Page to First Amendment to Security Agreement]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00205-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00205-of-00352.parquet"}]]